Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

China Pharma Holdings, Inc. (CPHI)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.4701-0.0613 (-11.53%)
At close: 03:59PM EST
0.4648 -0.01 (-1.13%)
After hours: 07:46PM EST
Advertisement
Sign in to post a message.
  • s
    sam
    Couldn’t hold on to big AH gains.Not a good sign for tomorrow
  • t
    tom
    Gastrodin.brain supplement,ageing,alheimers,memory
    Andrographis for lungs and arthritis.
    We need this company here
  • A
    Andrei
    in at .65 . . .is this an overnight hold or quick 10% wham bam thank u ma'am intraday trade. . .toot it & boot it??
  • A
    Andrei
    not enough comments in the last 8 hours to warrant a 2 day runner. . .
  • t
    tom
    Great products.wow.look at what some do
  • H
    H
    Bought at .69 a couple of months before and sold after close at 1.10.
  • L
    Louis
    An interesting insight into Q1 for $CHPI

    It shouldn’t come as a surprise that they have not excelled during COVID-19, though we can argue it shouldn’t have been hit so hard in losses being in the pharma industry. The CEO states this is partially due to the Chinese New Year slowing down production also.

    Whilst it’s not showing the boom I was hoping for, we may still see a bump from some much needed press release. If we can see this jump up beyond .50 breaking line, we will have made sufficient progress, imho.

    Source: https://finance.yahoo.com/amphtml/news/china-pharma-holdings-inc-reports-103000126.html
  • E
    Edward
    China Pharma Holdings (CPHI) Stock: Here’s Why It’s Flying!
    The company has several drugs on the Chinese market that are designed to treat the same types of symptoms that patients dealing with the coronavirus are experiencing. As such, the company’s already approved treatments may lead to the company being able to treat the condition.

    Moreover, CPHI currently owns the only bio manufacturing facility near the epicenter of the outbreak in China. So, not only does the company have drugs that may treat coronavirus, it has the facility and ability to make the treatments and get them to the targeted patient population very quickly.

    As investors start to realize the strategic advantage that the company has when it comes to the treatment of the coronavirus, we’re starting to see strong upward movement.

    https://alphastocknews.com/china-pharma-holdings-cphi-stock-heres-why-its-flying/2547/
    China Pharma Holdings, Inc. (NYSEAMERICAN: CPHI) is rocketing this morning, trading on gains of more than 50% early on. If you go digging for news, you’re not going to find any, but there is a good reason for the run. It seems as though the coronavir
    China Pharma Holdings, Inc. (NYSEAMERICAN: CPHI) is rocketing this morning, trading on gains of more than 50% early on. If you go digging for news, you’re not going to find any, but there is a good reason for the run. It seems as though the coronavir
    alphastocknews.com
  • E
    Ep
     

    Home

    Biotech

    Cannabis

    Basic Materials

    Consumer Goods

    Tech

    Tips, Tricks & Facts



    Home  Biotech Stock News

    Biotech Stock News

    China Pharma Holdings (CPHI) Stock: Here’s Why It’s Flying!

    By

     Joshua Rodriguez

     -

    February 3, 2020

    0



    China Pharma Holdings, Inc. (NYSEAMERICAN: CPHI) is rocketing this morning, trading on gains of more than 50% early on. If you go digging for news, you’re not going to find any, but there is a good reason for the run. It seems as though the coronavirus has triggered a short squeeze. Here’s what’s going on.
    Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

    Why CPHI Stock Is Soaring

    After seeing that no press releases or SEC filings came out of China Pharma Holdings this morning, I took to social media to see if I could find the catalyst that started the short squeeze. What I found is what I believe to be a clear reason for the run.
    All over StockTwits and other investing-related social media platforms, I’m seeing posts surrounding the strategic positioning of the company in the midst of a deadly outbreak. Ultimately, the new virus known as coronavirus is spreading through China and has found its way to different areas around the world.
    While there are no approved products that are designed to treat coronavirus, the virus is an upper respiratory viral infection. This is where the strategic positioning of CPHI comes in.

    The company has several drugs on the Chinese market that are designed to treat the same types of symptoms that patients dealing with the coronavirus are experiencing. As such, the company’s already approved treatments may lead to the company being able to treat the condition.
    Moreover, CPHI currently owns the only bio manufacturing facility near the epicenter of the outbreak in China. So, not only does the company have drugs that may treat coronavirus, it has the facility and ability to make the treatments and get them to the targeted patient population very quickly.
    As investors start to realize the strategic advantage that the company has when it comes to the treatment of the coronavirus, we’re starting to see strong upward movement.
    In fact, before today, CPHI was a pretty heavily shorted stock. Considering the upward movement, those with short positions are losing money quickly. This generally leads to short sellers racing to buy shares in an attempt to cover their positions and cut the bleeding. All in all, this is what a short squeeze is made of.

    What’s Next?

    Really, there’s no telling what’s in store for China Pharma Holdings. There’s no doubt that we’re likely to see some profit taking when investors feel the time is right, but after that, this may be a huge opportunity.
    After all, if CPHI does indeed announce that it is working to treat the coronavirus, given its strategic advantages, the stock could soar as the treatment could quickly become a blockbuster. At the end of the day, only time will tell what happens next, but the stock seems like a pretty strong bet!
    Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

    Don’t Miss The Next Big Story!

    Join our free mailing list below to receive real-time news alerts!

    Subscribe Today!

    * indicates required

    Email Address *

    First Name

    TAGS

    Biotech Stock News

    CPHI

    Penny Stocks

    Previous articleInsmed (INSM) Stock Rockets On Trial Results

    Next articleVaxart (VXRT) Stock Continues Skyward On Coronavirus Program



    Joshua Rodriguez

    Hi, Im' Joshua Rodriguez. I'm the founder of Alpha Stock News and CNA Finance. I'm also one of the brains behind iWatch Markets and am often published on websites like Benzinga, US News & World Report, Yahoo! Finance, and several others. To get in touch, contact me through my Contact Page.

    RELATED ARTICLESMORE FROM AUTHOR



    Vaxart (VXRT) Stock Continues Skyward On Coronavirus Program



    Insmed (INSM) Stock Rockets On Trial Results



    Chesapeake Energy (CHK) Stock Heads Up On Production News

    LEAVE A REPLY

    Save my name, email, and website in this browser for the next time I comment.
     Notify me of follow-up comments by email.
     Notify me of new posts by email.

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Get FREE Actionable Updates!



    Latest News



    Vaxart (VXRT) Stock Continues Skyward On Coronavirus Program

    Joshua Rodriguez - February 3, 2020

    0

    Vaxart Inc (NASDAQ: VXRT) is having yet another strong day in the market today, following up on the gains that we saw from the...



    China Pharma Holdings (CPHI) Stock: Here’s Why It’s Flying!

    February 3, 2020



    Insmed (INSM) Stock Rockets On Trial Results

    February 3, 2020

    Alpha Stock News is not an investment advisor or broker/dealer. The articles published on this website are designed for information and entertainment purposes only. Before making any investment decisions, it is important to do your due diligence and consider speaking with an investing professional.

    © Alpha Stock News 2019
  • T
    The Daddy
    Being bought by insiders...spikes of 1-3 million in trades...big % of a small company bought up....Will be a soldier for the roll out of 1 Billion vaccine doses this year...up from 500 million according to the government mouthpiece newspaper. In the same breath, said newspaper described vaccine roll out in terms of :"war" to keep competitive with other countries. In war, you use all your soldiers. This is a moonshot.
    Bullish
  • k
    kai
    Very likely the company has returned back to profitable, with the additional revenues from selling the sanitizers.
    Bullish
  • S
    SS
    short covering will push the price much much higher. No shares available for sale. That is why big gap between bid and ask.
    Bullish
  • k
    kai
    People have started to realize how important the Chinese medicines are in treating the coronavirus patients. Go CPHI, to the moon.
  • j
    joshua
    $CPHI is running for the top in the market after the company announced that it would be producing face masks in response to COVID-19. Here's what you need to know: https://alphastocknews.com/china-pharma-holdings-cphi-stock-heads-up-on-mask-production/3101/
  • k
    kai
    $3 by Friday, as the number of patients snowballing every day.
  • F
    Francisco
    Medical supplies is shortage in China according to the news.
  • T
    TAD
    CPHI - xploding. Here we go!!!
  • E
    Ep
    great sign cphi a lot positive result coming
    Bullish
  • T
    Timetravelerdos
    Check out the Good 3rd QTR results!
    China Pharma Holdings, Inc. Reports Third Quarter 2019 Financial Results

    China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended September 30, 2019.

    Third Quarter Highlights

    -- Revenue increased by 3.4% to $2.4 million in the third quarter 2019 from $2.3 million in the same period of 2018;

    -- Gross margin was 15.7% in the third quarter 2019, compared to 22.3% in the same period of 2018;

    -- Loss from operations was $0.6 million in the third quarter 2019 compared to $1.9 million in the same period of 2018, an improvement of $1.3 million;

    -- Net loss was $0.7 million in the third quarter 2019 compared to $1.9 million in the same period of 2018. Loss per common share was $0.02 per basic and diluted share in the third quarter 2019, compared to $0.04 per basic and diluted share in the same period of 2018.

    Ms. Zhilin Li, China Pharma's Chairman and CEO, commented, "We experienced negative effects on our sales from the strict implementation of the government policy of controlling the proportion of the spending on drugs to the patients' total expenditures in hospitals in recent quarters. Management endeavors to vigorously promote sales through active participation in recent provincial market openings to solicit new drug tender offers and allow China Pharma to expand its presence in these markets." Ms. Li continued, "In addition, we are experiencing sustained pressure from the more stringent requirements of drug registration standards, consistency evaluations, which has created a challenging environment in our industry during this period. We will continue actively adapting to the state policy guidance and further evaluate market conditions for our current existing products, pipeline products, and competition in the market, in order to optimize our development strategy. We will simultaneously actively implement the launch of our nutrition product."

    Third Quarter Results

    Revenue increased by 3.4% to $2.4 million for the three months ended September 30, 2019, as compared to $2.3 million for the three months ended September 30, 2018.

    Gross profit for the three months ended September 30, 2019 was $0.4 million, as compared to $0.5 million during the same period in 2018. Our gross profit margin in the three months ended September 30, 2019 was 15.7% as compared to 22.3% during the same period in 2018. The decrease in our gross profit margin was mainly due to the increased ratio of fixed cost to revenue.

    Our selling expenses for the three months ended September 30, 2019 and 2018 were $0.6 million and $0.9 million, respectively. Selling expenses accounted for 25.8% of the total revenue in the three months ended September 30, 2019, as compared to 40.3% during the same period in 2018.

    Our general and administrative expenses were $0.3 million for each of the three months ended September 30, 2019 and 2018. General and administrative expenses accounted for 14.0% and 14.2% of our total revenues in the three months ended September 30, 2019 and 2018, respectively.

    Our research and development expenses for the three months ended September 30, 2019 were $0.04 million, as compared to $0.06 million in the same period in 2018. Research and development expenses accounted for 1.7% and 2.7% of our total revenues in the three months ended September 30, 2019 and 2018, respectively. The consistency evaluations discussed under the "Business Overview & Recent Developments" section hereof is expected to have a significant impact on all generic products not only in our pipeline products, but also throughout the existing Chinese market for similar generic products. Because of the continuous introduction of detailed implementation rules under this policy, our pipeline products did not experience any further development in the third quarter of 2019.

    Our bad debt expenses for the three months ended September 30, 2019 was $0.03 million, as compared to $1.13 million for the same period in 2018. The decrease of bad debt expenses in this period was mainly due to the decrease in the amount of accounts receivable that is turning to over 2 years old in this period. Our bad debt allowance estimate requires 70% of accounts receivable that are between 365 days and 720 days old, and 100% of accounts receivable that are greater than 720 days old.

    Net loss for the three months ended September 30, 2019 was $0.7 million, or $0.02 per basic and diluted common share, as compared to a net loss of $1.9 million, or $0.04 per basic and diluted common share, for the same period a year ago. The decrease in net loss was mainly the result of controls on expenditures outweighed the impact of decrease in gross profit margin.

    Nine Months Results

    For the nine months ended September 30, 2019, our
  • k
    kai
    As expected, the company has returned back to profitable again, the first time in nearly nine years. Significant.
    Bullish
Advertisement
Advertisement